Cavazzoni Rejoins Pfizer. Why Must Vendors ReAnalyse Pfizer Org Charts?
In February 2025, Pfizer appointed Patricia Cavazzoni as its new Chief Medical Officer. She replaced Aida Habtezion, who was leaving the company. For most vendors selling into Pfizer, that announcement came and went without a response. That is the actual problem. A CMO change at a company like Pfizer does not just affect one seat. It reshapes reporting lines, redistributes budget authority, and quietly shifts who is actually making vendor decisions across regulatory, pharmacovigilance, and medical functions. By the time most sales teams update their Pfizer org chart or adjust their outreach, the window has already narrowed. This blog breaks down what the domino effect actually means, what moves inside Pfizer's organizational structure when a senior leader exits, and how GenAI-driven org chart intelligence changes the vendor response entirely. What Is Pfizer's CMO Domino Effect? The domino effect, in this context, is a specific, predictable sequence that follows any senior le...